low - Clinical-stage biotech valuations driven primarily by binary clinical/regulatory events rather than economic cycles. Rare disease drug demand is non-discretionary and insulated from GDP fluctuations. However, capital markets access for funding is cyclical: risk-off environments compress biotech valuations and impair equity financing ability, creating liquidity risk for cash-burning development companies.

Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (sebetralstat revenue potentially 2028+). Clinical-stage biotechs are long-duration assets with no near-term earnings, making them particularly sensitive to risk-free rate changes. Higher rates also increase competition from fixed income, reducing speculative capital flows into high-risk biotech. Financing costs rise if debt is utilized, though KalVista primarily equity-funded.

growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and biotech-focused hedge funds willing to underwrite binary event risk. Typical holders include specialist healthcare funds, venture capital crossover investors, and retail momentum traders. Not suitable for value or income investors given no earnings, dividends, or tangible book value. Investment thesis predicated on 5-10x return potential if sebetralstat achieves approval, offset by total loss risk on clinical failure.